Literature DB >> 11010968

Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family.

K Tsuchida1, K Y Arai, Y Kuramoto, N Yamakawa, Y Hasegawa, H Sugino.   

Abstract

Follistatin is an activin-binding protein that prevents activin from binding to its receptors and neutralizes its activity. Follistatin also binds bone morphogenetic proteins (BMPs). In this study, we report the identification of a novel follistatin-like protein from mouse. The mouse cDNA encodes a 256-residue precursor and most likely a mouse homologue of human FLRG, which was found at the breakpoint of the chromosomal rearrangement in a B-cell line. Whereas follistatin has three follistatin domains, which are presumed to be growth factor binding motifs, FLRG possesses only two follistatin domains. Northern blotting revealed that mRNAs for FLRG were abundantly expressed in heart, lung, kidney, and testis in mouse. The recombinant mouse FLRG proteins were found to have binding activity for both activin and bone morphogenetic protein-2. Like follistatin, FLRG has higher affinity for activin than for BMP-2. The FLRG protein inhibited activin-induced and BMP-2-induced transcriptional responses in a dose-dependent manner. Glutathione S-transferase fusion proteins encoding various regions of FLRG were produced and studied. Ligand blotting using (125)I-activin revealed that the COOH-terminal region containing the second follistatin domain was able to bind activin. Our finding implies that cellular signaling by activin and BMPs is tightly regulated by multiple members of the follistatin family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11010968     DOI: 10.1074/jbc.M006114200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

Authors:  Kevin J Morine; Lawrence T Bish; Joshua T Selsby; Jeffery A Gazzara; Klara Pendrak; Meg M Sleeper; Elisabeth R Barton; Se-Jin Lee; H Lee Sweeney
Journal:  Muscle Nerve       Date:  2010-11       Impact factor: 3.217

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

3.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

4.  Human placenta and fetal membranes express follistatin-related gene mRNA and protein.

Authors:  P Ciarmela; P Florio; P Toti; A Franchini; V Maguer-Satta; C Ginanneschi; E Ottaviani; F Petraglia
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

5.  Periostin secreted by mesenchymal stem cells supports tendon formation in an ectopic mouse model.

Authors:  Sandra Noack; Virginia Seiffart; Elmar Willbold; Sandra Laggies; Andreas Winkel; Sandra Shahab-Osterloh; Thilo Flörkemeier; Falk Hertwig; Christine Steinhoff; Ulrike A Nuber; Gerhard Gross; Andrea Hoffmann
Journal:  Stem Cells Dev       Date:  2014-06-12       Impact factor: 3.272

6.  Hypoxia enhances the expression of follistatin-like 3 in term human trophoblasts.

Authors:  T Biron-Shental; W T Schaiff; E Rimon; T L Shim; D M Nelson; Y Sadovsky
Journal:  Placenta       Date:  2007-10-23       Impact factor: 3.481

7.  Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.

Authors:  Kevin J Morine; Lawrence T Bish; Klara Pendrak; Meg M Sleeper; Elisabeth R Barton; H Lee Sweeney
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

8.  Agrin binds BMP2, BMP4 and TGFbeta1.

Authors:  László Bányai; Peter Sonderegger; László Patthy
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

Review 9.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.